SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been reported to be beneficial not only in improving blood glucose in patients with type 2 diabetes but also in reducing the risk of cardiovascular events and heart failure [1, 2] and in preventing the progression of chronic renal failure [3, 4].